FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3020234497> ?p ?o ?g. }

• W3020234497 endingPage "320" @default.
• W3020234497 startingPage "311" @default.
• W3020234497 abstract "Rationale & Objective Evidence for the efficacy of direct oral anticoagulants (DOACs) to prevent cardiovascular (CV) events and mortality in older individuals with a low estimated glomerular filtration rate (eGFR) is lacking. We sought to characterize the association of oral anticoagulant use with CV morbidity in elderly patients with or without reductions in eGFRs, comparing DOACs with vitamin K antagonists (VKAs). Study Design Population-based retrospective cohort study. Settings & Participants All individuals 66 years or older with an initial prescription for oral anticoagulants dispensed in Ontario, Canada, from 2009 to 2016. Exposure DOACs (apixaban, dabigatran, and rivaroxaban) compared with VKAs by eGFR group (≥60, 30-59, and <30 mL/min/1.73 m2). Outcomes The primary outcome was a composite of a CV event (myocardial infarction, revascularization, or ischemic stroke) or mortality. Secondary outcomes were CV events alone, mortality, and hemorrhage requiring hospitalization. Analytical Approach High-dimensional propensity score matching of DOAC to VKA users and Cox proportional hazards regression. Results 27,552 new DOAC users were matched to 27,552 new VKA users (median age, 78 years; 49% women). There was significantly lower risk for CV events or mortality among DOAC users compared with VKA users (event rates of 79.78 vs 99.77 per 1,000 person-years, respectively; HR, 0.82 [95% CI, 0.75-0.90]) and lower risk for hemorrhage (event rates of 10.35 vs 16.77 per 1,000 person-years, respectively; HR, 0.73 [95% CI, 0.58-0.91]). There was an interaction between eGFR and the association of anticoagulant class with the primary composite outcome (P < 0.02): HRs of 1.01 [95% CI, 0.92-1.12], 0.83 [95% CI, 0.75-0.93], and 0.75 [95% CI, 0.51-1.10] for eGFRs of ≥60, 30 to 59, and <30 mL/min/1.73 m2. No interaction was detected for the outcome of hemorrhage. Limitations Retrospective observational study design limits causal inference; dosages of DOACs and international normalized ratio values were not available; low event rates in some subgroups limited statistical power. Conclusions DOACs compared with VKAs were associated with lower risk for the composite of CV events or mortality, an association for which the strength was most apparent among those with reduced eGFRs. The therapeutic implications of these findings await further study. Evidence for the efficacy of direct oral anticoagulants (DOACs) to prevent cardiovascular (CV) events and mortality in older individuals with a low estimated glomerular filtration rate (eGFR) is lacking. We sought to characterize the association of oral anticoagulant use with CV morbidity in elderly patients with or without reductions in eGFRs, comparing DOACs with vitamin K antagonists (VKAs). Population-based retrospective cohort study. All individuals 66 years or older with an initial prescription for oral anticoagulants dispensed in Ontario, Canada, from 2009 to 2016. DOACs (apixaban, dabigatran, and rivaroxaban) compared with VKAs by eGFR group (≥60, 30-59, and <30 mL/min/1.73 m2). The primary outcome was a composite of a CV event (myocardial infarction, revascularization, or ischemic stroke) or mortality. Secondary outcomes were CV events alone, mortality, and hemorrhage requiring hospitalization. High-dimensional propensity score matching of DOAC to VKA users and Cox proportional hazards regression. 27,552 new DOAC users were matched to 27,552 new VKA users (median age, 78 years; 49% women). There was significantly lower risk for CV events or mortality among DOAC users compared with VKA users (event rates of 79.78 vs 99.77 per 1,000 person-years, respectively; HR, 0.82 [95% CI, 0.75-0.90]) and lower risk for hemorrhage (event rates of 10.35 vs 16.77 per 1,000 person-years, respectively; HR, 0.73 [95% CI, 0.58-0.91]). There was an interaction between eGFR and the association of anticoagulant class with the primary composite outcome (P < 0.02): HRs of 1.01 [95% CI, 0.92-1.12], 0.83 [95% CI, 0.75-0.93], and 0.75 [95% CI, 0.51-1.10] for eGFRs of ≥60, 30 to 59, and <30 mL/min/1.73 m2. No interaction was detected for the outcome of hemorrhage. Retrospective observational study design limits causal inference; dosages of DOACs and international normalized ratio values were not available; low event rates in some subgroups limited statistical power. DOACs compared with VKAs were associated with lower risk for the composite of CV events or mortality, an association for which the strength was most apparent among those with reduced eGFRs. The therapeutic implications of these findings await further study." @default.
• W3020234497 created "2020-05-01" @default.
• W3020234497 creator A5001731019 @default.
• W3020234497 creator A5017404988 @default.
• W3020234497 creator A5022265533 @default.
• W3020234497 creator A5022935489 @default.
• W3020234497 creator A5028012174 @default.
• W3020234497 creator A5034701753 @default.
• W3020234497 creator A5036326268 @default.
• W3020234497 creator A5040983228 @default.
• W3020234497 creator A5056937094 @default.
• W3020234497 creator A5060951830 @default.
• W3020234497 creator A5072092228 @default.
• W3020234497 creator A5075474387 @default.
• W3020234497 creator A5079669974 @default.
• W3020234497 creator A5084271635 @default.
• W3020234497 creator A5088941984 @default.
• W3020234497 date "2020-09-01" @default.
• W3020234497 modified "2023-10-17" @default.
• W3020234497 title "Risk of Cardiovascular Events and Mortality Among Elderly Patients With Reduced GFR Receiving Direct Oral Anticoagulants" @default.
• W3020234497 cites W1564690174 @default.
• W3020234497 cites W1867701655 @default.
• W3020234497 cites W1966297507 @default.
• W3020234497 cites W1967862917 @default.
• W3020234497 cites W1994804878 @default.
• W3020234497 cites W2049491523 @default.
• W3020234497 cites W2050091824 @default.
• W3020234497 cites W2063195683 @default.
• W3020234497 cites W2068634821 @default.
• W3020234497 cites W2074119210 @default.
• W3020234497 cites W2098837786 @default.
• W3020234497 cites W2108064339 @default.
• W3020234497 cites W2136796090 @default.
• W3020234497 cites W2141610267 @default.
• W3020234497 cites W2144939065 @default.
• W3020234497 cites W2155965977 @default.
• W3020234497 cites W2159370562 @default.
• W3020234497 cites W2163278718 @default.
• W3020234497 cites W2168106976 @default.
• W3020234497 cites W2168713667 @default.
• W3020234497 cites W2200136802 @default.
• W3020234497 cites W2216123836 @default.
• W3020234497 cites W2251160653 @default.
• W3020234497 cites W2284187917 @default.
• W3020234497 cites W2286779217 @default.
• W3020234497 cites W2536529040 @default.
• W3020234497 cites W2554062859 @default.
• W3020234497 cites W2564869058 @default.
• W3020234497 cites W2589662789 @default.
• W3020234497 cites W2611798950 @default.
• W3020234497 cites W2735068920 @default.
• W3020234497 cites W2746462642 @default.
• W3020234497 cites W2749380187 @default.
• W3020234497 cites W2769177651 @default.
• W3020234497 cites W2788040427 @default.
• W3020234497 cites W2793022508 @default.
• W3020234497 cites W2810139214 @default.
• W3020234497 cites W2942626415 @default.
• W3020234497 doi "https://doi.org/10.1053/j.ajkd.2020.02.446" @default.
• W3020234497 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32333946" @default.
• W3020234497 hasPublicationYear "2020" @default.
• W3020234497 type Work @default.
• W3020234497 sameAs 3020234497 @default.
• W3020234497 citedByCount "17" @default.
• W3020234497 countsByYear W30202344972020 @default.
• W3020234497 countsByYear W30202344972021 @default.
• W3020234497 countsByYear W30202344972022 @default.
• W3020234497 countsByYear W30202344972023 @default.
• W3020234497 crossrefType "journal-article" @default.
• W3020234497 hasAuthorship W3020234497A5001731019 @default.
• W3020234497 hasAuthorship W3020234497A5017404988 @default.
• W3020234497 hasAuthorship W3020234497A5022265533 @default.
• W3020234497 hasAuthorship W3020234497A5022935489 @default.
• W3020234497 hasAuthorship W3020234497A5028012174 @default.
• W3020234497 hasAuthorship W3020234497A5034701753 @default.
• W3020234497 hasAuthorship W3020234497A5036326268 @default.
• W3020234497 hasAuthorship W3020234497A5040983228 @default.
• W3020234497 hasAuthorship W3020234497A5056937094 @default.
• W3020234497 hasAuthorship W3020234497A5060951830 @default.
• W3020234497 hasAuthorship W3020234497A5072092228 @default.
• W3020234497 hasAuthorship W3020234497A5075474387 @default.
• W3020234497 hasAuthorship W3020234497A5079669974 @default.
• W3020234497 hasAuthorship W3020234497A5084271635 @default.
• W3020234497 hasAuthorship W3020234497A5088941984 @default.
• W3020234497 hasBestOaLocation W30202344971 @default.
• W3020234497 hasConcept C126322002 @default.
• W3020234497 hasConcept C127413603 @default.
• W3020234497 hasConcept C159641895 @default.
• W3020234497 hasConcept C167135981 @default.
• W3020234497 hasConcept C17923572 @default.
• W3020234497 hasConcept C207103383 @default.
• W3020234497 hasConcept C2776301958 @default.
• W3020234497 hasConcept C2778661090 @default.
• W3020234497 hasConcept C2778810321 @default.
• W3020234497 hasConcept C2779161974 @default.
• W3020234497 hasConcept C2779668873 @default.
• W3020234497 hasConcept C2780638905 @default.
• W3020234497 hasConcept C2780645631 @default.

• next